NetworkNewsBreaks – Lexaria Bioscience Corp. (CS
Post# of 721
(Total Views: 169)
Posted On: 08/27/2019 4:08:41 PM
NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Receives DehydraTECH Patent for Pharmaceutical Applications of Cannabinoids to Treat Certain Conditions
Biotechnology company and global drug delivery platform innovator Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) today announced its receipt of a new patent granted in Australia: #2016367037 / Grant Date August 15, 2019 – “Stable ready-to-drink beverage compositions comprising lipophilic active agents.” According to the update, this increases Lexaria’s portfolio to 16 awarded patents protecting its DehydraTECH(TM) drug delivery platform, with eight in the USA and eight in Australia. The new Australian patent, together with Australian Patent #2016367036 announced on August 15, 2019, are the first granted in Lexaria’s second and third patent families that differ from the company’s original patent family, “Food and beverage compositions infused with lipophilic active agents and methods of use thereof.” These new patents include claims for DehydraTECH technology with respect to food and beverage use and also, for the first time, for pharmaceutical applications for delivery of cannabinoids as methods of treating certain conditions. These include, but are not limited to heart disease, neurological diseases, obesity, metabolic and appetite disorders, hepatic diseases, diabetes, cancer via chemotherapy, irritable bowel syndrome (“IBS”), marijuana abuse, and opioid, alcohol, nicotine or cocaine addiction.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Biotechnology company and global drug delivery platform innovator Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) today announced its receipt of a new patent granted in Australia: #2016367037 / Grant Date August 15, 2019 – “Stable ready-to-drink beverage compositions comprising lipophilic active agents.” According to the update, this increases Lexaria’s portfolio to 16 awarded patents protecting its DehydraTECH(TM) drug delivery platform, with eight in the USA and eight in Australia. The new Australian patent, together with Australian Patent #2016367036 announced on August 15, 2019, are the first granted in Lexaria’s second and third patent families that differ from the company’s original patent family, “Food and beverage compositions infused with lipophilic active agents and methods of use thereof.” These new patents include claims for DehydraTECH technology with respect to food and beverage use and also, for the first time, for pharmaceutical applications for delivery of cannabinoids as methods of treating certain conditions. These include, but are not limited to heart disease, neurological diseases, obesity, metabolic and appetite disorders, hepatic diseases, diabetes, cancer via chemotherapy, irritable bowel syndrome (“IBS”), marijuana abuse, and opioid, alcohol, nicotine or cocaine addiction.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)